ProfessorNagyHabib

Summary

Nagy Habib ChM, FRCS is a Professor of Surgery and a leading translational researcher in liver cancer and its treatment He pioneered the first clinical trial in the use of adenovirus for the treatment of liver cancer, as well as the use of plasmid gene therapy for hydrodynamic gene delivery He is the first person in the West to publish a clinical trial on the use of adult bone marrow derived stem cells and RNA activation for the treatment of patients with liver insufficiency and liver cancer. Nagy is currently Lead Clinician and Head of the Department of liver Surgery at Imperial College London at the Hammersmith Campus. In June 2007 he was also appointed Pro Rector for Commercial Affairs and member of the College Management Board. He held a gold award from the Advisory Committee for Clinical Excellence, which is given in recognition of exceptional contributions by NHS consultants.

Notable Achievements:

• Performed first-living related liver transplant in Africa & the Middle East 1993
• Saturday TIMES Magazine top surgeon 2011
• Takreem Laureate winner 2012 (The Takreem Foundation honours Arabs in the fields of science, education, leadership and culture
• Inventor of the Habib 4x liver resection device (AngioDynamics Inc 2015)
• Inventor of the Habib EndoHPB (Boston Scientific 2018) (won an Edison Gold award for Medical Innovation 2020)
• Co-Founder of MiNA Therapeutics Ltd (RNA therapeutics),
• Founder of EMcision Ltd (medical device innovation),Apterna Ltd (aptamer development), Dawn Therapeutics ltd (gene therapy)
• Member of the French Académie Nationale de Chirurgie 2015
• Honorary Professorships awarded in Egypt, China, Romania & Greece
• Publications in gene therapy, stem cell therapy, oligionuleotide research & surgical technique
• American Association of Cell & Gene Therapy (ASCGT) Annual Meeting Invited Scientific Session Speaker May 2024

Selected Publications

Journal Articles